Pancragen Peptide 20mg

Description

What Is Pancragen Peptide?

Pancragen peptide is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Trp (KEDW), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Pancragen belongs to the Khavinson bioregulator peptides class — short regulatory peptides (2–4 amino acids) that modulate tissue-specific gene expression at physiological concentrations. Pancragen’s primary target is pancreatic tissue, where it has been studied for its capacity to normalize gene expression patterns associated with insulin-producing beta cell function, glucose metabolism regulation, and pancreatic tissue homeostasis in aging models.

As a pancreas bioregulator, pancragen operates through the Khavinson epigenetic mechanism — direct interaction with complementary DNA sequences in the promoter regions of pancreatic-specific genes, modulating transcription rather than acting through receptor agonism or enzyme inhibition. This fundamentally different approach to tissue function restoration has been studied across four decades of bioregulation research. PrymaLab Pancragen 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research applications.

Pancragen 20mg: Key Specifications

How Pancragen Works: Bioregulator Mechanism of Action

Pancragen operates through the established Khavinson model of peptide bioregulation, in which short peptides interact with complementary DNA sequences in the promoter regions of tissue-specific genes. For pancragen, the target gene clusters are those governing pancreatic beta cell function, insulin synthesis and secretion, and pancreatic tissue maintenance during biological aging.

Pancreatic Gene Expression Modulation

Research from the Khavinson group demonstrates that pancragen modulates the expression of genes critical to pancreatic endocrine function, including genes involved in insulin biosynthesis, beta cell glucose sensing via glucokinase pathways, and pancreatic transcription factors (such as PDX-1) that maintain beta cell identity and function throughout the lifespan. In aged pancreatic tissue models, pancragen administration was associated with restoration of gene expression patterns toward profiles characteristic of younger, functionally competent tissue.

Beta Cell Function and Glucose Homeostasis

The primary research interest in pancragen centers on its effects on pancreatic beta cell function and glucose metabolism regulation. Preclinical studies from the St. Petersburg Institute have examined pancragen’s impact on insulin secretion capacity, beta cell proliferation markers, and glucose tolerance parameters in aged and metabolically stressed animal models. The peptide’s mechanism — modulating gene expression rather than directly stimulating insulin release — represents a distinct research approach compared to conventional secretagogue compounds that act on sulfonylurea receptors or GLP-1 pathways.

Pancreatic Tissue Homeostasis in Aging

Age-related decline in pancreatic function is a major focus of gerontological research, as beta cell mass and insulin secretion capacity decrease progressively with aging. Pancragen has been studied as a potential bioregulatory intervention to slow or partially reverse this age-related functional decline by restoring the transcriptional programs that maintain pancreatic tissue identity and secretory capacity. This anti-aging application aligns with the broader Khavinson hypothesis that short peptides can be used to counteract age-related epigenetic changes in specific organ systems.

Pancragen Peptide Benefits: What Research Shows

The following research context reflects published preclinical and clinical gerontology literature from the Khavinson research program. PrymaLab Pancragen 20mg is supplied exclusively for research purposes.

Glucose Metabolism and Insulin Function

Khavinson and colleagues have published data demonstrating that pancragen administration in aged animal models was associated with improved glucose tolerance, enhanced insulin secretion responses to glucose challenge, and normalization of fasting glucose levels. These effects are attributed to the restoration of beta cell gene expression patterns that deteriorate during biological aging, including upregulation of insulin gene transcription and glucokinase activity normalization.

Pancreatic Anti-aging Effects

In gerontological research models, pancragen has been studied alongside other Khavinson bioregulators for its potential to extend functional lifespan of pancreatic tissue. Published data indicates that bioregulator peptide administration in aging animal cohorts was associated with maintained pancreatic function at ages where control animals showed significant functional decline, supporting the hypothesis that short regulatory peptides can modulate the rate of age-related organ function loss.

Pancreatic Cytoprotection

Preliminary preclinical data has examined pancragen’s effects on pancreatic cell survival under metabolic stress conditions, including oxidative stress and glucotoxicity models relevant to type 2 diabetes research. These cytoprotective properties are hypothesized to result from gene expression modulation affecting antioxidant defense enzymes and cellular stress response pathways in pancreatic tissue.

Pancragen vs. Other Metabolic Bioregulators: Key Differences

How to Store and Handle PrymaLab Pancragen 20mg

1. Store lyophilized at −20°C. Keep the sealed vial desiccated and protected from light. Lyophilized pancragen is stable for 24+ months under these conditions.
2. Allow vial to reach room temperature before opening. This prevents condensation from degrading the peptide powder.
3. Reconstitute with appropriate sterile solvent. Use bacteriostatic water or sterile saline. Add solvent slowly along the vial wall to avoid foaming.
4. Use reconstituted solution within 2–4 weeks. Store at 2–8°C. Mark the reconstitution date on the label.
5. Avoid repeated freeze-thaw cycles. Aliquot into single-use portions if needed.
6. Retain the Certificate of Analysis. Record the lot number and keep the COA for traceability.

Why Choose PrymaLab Pancragen 20mg?

PrymaLab supplies Pancragen 20mg as a high-purity research-grade bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each production batch ships with a unique lot number and Certificate of Analysis documenting purity, identity, and testing methodology. Independent third-party analytical testing ensures unbiased results and full traceability for GLP-compliant research environments and peer-reviewed publication standards.

Frequently Asked Questions About Pancragen Peptide

What is pancragen and what tissue does it target?

Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp, KEDW) belonging to the Khavinson bioregulator peptide class. It targets pancreatic tissue — specifically insulin-producing beta cells and the broader endocrine and exocrine pancreas. Pancragen was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology and has been studied for its capacity to modulate pancreatic gene expression patterns associated with glucose metabolism and aging.

How does pancragen work as a pancreas bioregulator?

Pancragen operates through the Khavinson bioregulation mechanism — direct interaction with complementary DNA sequences in the promoter regions of pancreatic-specific genes. Rather than stimulating receptors or inhibiting enzymes, pancragen modulates transcription of genes governing beta cell function, insulin biosynthesis, and pancreatic tissue homeostasis. This epigenetic approach aims to restore gene expression patterns that deteriorate during biological aging.

What is the difference between pancragen and ovagen?

Both are Khavinson bioregulator peptides targeting metabolic organs, but they differ in tissue specificity. Pancragen (KEDW) targets pancreatic tissue — focusing on beta cell function, insulin pathways, and glucose metabolism. Ovagen targets liver and gastrointestinal tissue — focusing on hepatic function, detoxification pathways, and GI barrier integrity. Research protocols sometimes use both peptides together for comprehensive metabolic system support.

How should pancragen be stored?

Store lyophilized pancragen at −20°C, desiccated and protected from light, for stability of 24+ months. After reconstitution with sterile solvent, refrigerate at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles by aliquoting into single-use portions.

What testing does PrymaLab perform on pancragen?

Every batch is tested at ≥98% purity by reverse-phase HPLC and identity-verified by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. Testing is conducted by independent analytical laboratories for unbiased quality verification and full traceability.

Research Disclaimer

For Research Use Only. PrymaLab Pancragen 20mg is intended exclusively for qualified preclinical research use. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Pancragen has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described are drawn from published preclinical and gerontological literature. Researchers are responsible for ensuring compliance with all applicable regulations.